UCB's Kremers Urban Sale Deal Lapses, Divestiture Plan On - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 18, 2:20PM CST
UCB (UCBJF), Advent International and Avista Capital Partners announced their decision to mutually terminate their deal for the acquisition of UCB's Kremers Urban.
LCI: 42.29 (+1.79), VRX: 140.33 (-0.22), SCMP: 13.75 (+0.44)
UCB Reports Phase III Data on Epilepsy Drug, To File in 2015 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 09, 1:50PM CST
UCB SA (UCBJF) announced positive primary efficacy and safety data from its latest phase III study on its epilepsy candidate, brivaracetam.
LCI: 42.29 (+1.79), VRX: 140.33 (-0.22), SCMP: 13.75 (+0.44)
UCB-Daiichi Sankyo Ink Deal to Sell Vimpat in Japan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 01, 2:20PM CST
UCB SA (UCBJF) and Daiichi Sankyo have signed a deal to jointly commercialize Vimpat for the treatment of epilepsy in Japan.
IPXL: 31.32 (+0.26), VRX: 140.33 (-0.22), SCMP: 13.75 (+0.44)
Immunomedics' Veltuzumab Receives Orphan Drug Status - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 24, 3:20PM CST
Immunomedics' (IMMU) anti-CD20 antibody, veltuzumab, was granted an orphan drug status in the U.S. for the treatment of pemphigus.
BIIB: 340.89 (+5.13), IMMU: 4.41 (+0.13)
Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
Arpita Dutt - Zacks Investment Research - Wed Nov 19, 12:00AM CST
Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
ACT: 254.20 (-1.68), QLTI: 3.72 (+0.08), VRX: 140.33 (-0.22), AGN: 210.12 (+0.95), SHPG: 209.29 (+0.07), AUXL: 34.40 (+0.18), ABBV: 66.21 (+1.86), SNY: 46.35 (+0.50), ABT: 45.70 (-0.02), ENDP: 72.10 (+0.34), AKRX: 36.47 (+0.43), PFE: 31.42 (-0.03), INCY: 71.57 (+1.99), SLXP: 114.92 (-1.18), MYL: 56.97 (+0.39), AMGN: 160.67 (+3.15), LLY: 70.16 (+0.42), GSK: 42.85 (+0.11), BMY: 59.15 (-0.01), ACHN: 13.06 (+1.22), MRK: 57.46 (+0.25), AZN: 70.44 (+0.26), ICPT: 151.49 (+5.85), TEVA: 57.09 (+0.33), NVS: 93.91 (+0.66)
Pharma Industry Outlook: M&A, Licensing Abound - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Wed Nov 19, 12:00AM CST
Pharma Industry Outlook: M&A, Licensing Abound - Zacks Analyst Interviews
ACT: 254.20 (-1.68), QLTI: 3.72 (+0.08), VRX: 140.33 (-0.22), AGN: 210.12 (+0.95), SHPG: 209.29 (+0.07), AUXL: 34.40 (+0.18), ABBV: 66.21 (+1.86), SNY: 46.35 (+0.50), ABT: 45.70 (-0.02), ENDP: 72.10 (+0.34), AKRX: 36.47 (+0.43), PFE: 31.42 (-0.03), INCY: 71.57 (+1.99), SLXP: 114.92 (-1.18), MYL: 56.97 (+0.39), AMGN: 160.67 (+3.15), LLY: 70.16 (+0.42), GSK: 42.85 (+0.11), BMY: 59.15 (-0.01), ACHN: 13.06 (+1.22), MRK: 57.46 (+0.25), AZN: 70.44 (+0.26), ICPT: 151.49 (+5.85), TEVA: 57.09 (+0.33), NVS: 93.91 (+0.66)
Will Catalyst Pharmaceuticals' (CPRX) Loss Narrow in Q3? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 4:30PM CST
Catalyst Pharmaceuticals Inc, Inc. (CPRX) is expected to report third-quarter 2014 results on Nov 13.
MNK: 97.84 (-0.29), BMRN: 88.18 (+0.89), CPRX: 2.90 (-0.02)
UCB to Sell Generics Business, Focus on Core Segments - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 4:30PM CST
UCB SA (UCBJF) entered into an agreement with Advent International and Avista Capital Partners for the sale of its specialty generics subsidiary for $1.525 billion.
LCI: 42.29 (+1.79), LLY: 70.16 (+0.42), GSK: 42.85 (+0.11), NVS: 93.91 (+0.66)
UCB jettisons U.S. generic business
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 6:20AM CST
UCB-Amgen Reveals Positive Data on Romosozumab for PMO - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 17, 5:40PM CDT
UCB SA (UCBJF) and Amgen announced positive results from exploratory analyses of a phase II study on romosozumab in postmenopausal women with low bone mineral density.
GILD: 91.29 (+1.84), AMGN: 160.67 (+3.15), LLY: 70.16 (+0.42)
Roche's (RHHBY) RoActemra Gets EU Approval for Early RA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 09, 4:20PM CDT
Positive news flowed in at Roche (RHHBY) when its RA drug RoActemra received approval from the European Commission to treat patients suffering from early RA who have previously not been treated with methotrexate (MTX).
AGN: 210.12 (+0.95), ABBV: 66.21 (+1.86)
UCB's Epilepsy Drug Vimpat's Label Expanded in the U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 02, 3:45PM CDT
UCB's (UCBJF) Vimpat has been approved in the U.S. as monotherapy for the treatment of partial-onset seizures in epilepsy patients aged 17 years and above.
AGN: 210.12 (+0.95), LCI: 42.29 (+1.79), ENDP: 72.10 (+0.34)
UCB Files Patent Infringement Lawsuit vs. Actavis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 28, 3:40PM CDT
Actavis has filed an ANDA with the FDA seeking marketing approval for its generic version of UCB's Neupro. In response, UCB filed a lawsuit against Actavis.
MNK: 97.84 (-0.29), ACT: 254.20 (-1.68), AKRX: 36.47 (+0.43)
Global Rheumatoid Arthritis Drugs Market 2014-2018
M2 - Mon Jul 28, 6:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tv2rn2/global_rheumatoid) has announced the addition of the "Global Rheumatoid Arthritis Drugs Market 2014-2018" report to their offering. RA is a chronic disease that leads to inflammation and pain in the human body's joints such as wrists, fingers, knees, feet, and ankles. In addition, it causes inflammation of the tissues that surround the joints and in other organs. The symptoms of RA begin slowly, usually just mild pain around the joints coupled with stiffness and fatigue, and in the later stages it causes inflammation of the joints. It can occur at any age, even in children, which is called juvenile arthritis. The disease is three times more common in women than in men. Genetic and environmental elements are known to contribute in the development of RA. The analysts forecast the Global Rheumatoid Arthritis Drugs market will grow at a CAGR of 4.09 percent over the period 2013-2018. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Competitive Assessment of Top Drugs 08. Five Forces Analysis 09. Market Segmentation by Category 10. Geographical Segmentation 11. Buying Criteria 12. Rate of Incidence and Prevalence 13. Pipeline Snapshot 14. Market Growth Drivers 15. Drivers and their Impact 16. Market Challenges 17. Impact of Drivers and Challenges 18. Market Trends 19. Trends and their Impact 20. Vendor Landscape 21. Key Vendor Analysis 22. Other Reports in this Series Companies Mentioned: - AbbVie Inc. - Amgen Inc. - Bristol-Myers Squibb Co. - F. Hoffmann-La Roche Ltd. - Janssen Pharmaceuticals Inc. - Pfizer Inc. - AB Science SA - Astellas Pharma Inc. - AstraZeneca plc - Biogen Idec Inc. - Boehringer Ingelheim GmbH - Celgene Corp. - Daiichi Sankyo Co. Ltd. - Eli Lilly & Co. - GE Healthcare Co. - Genmab A/S - GSK plc - Incyte Corp. - Merck & Co. Inc. - Mitsubishi Tanabe Pharma Corp. - Novartis AG - Novo Nordisk A/S - Rigel Pharmaceuticals Inc. - Sanofi - Takeda Pharmaceutical Co. Ltd. - UCB SA - Vertex Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/tv...rheumatoid
BIIB: 340.89 (+5.13), VRTX: 115.15 (+1.40), PFE: 31.42 (-0.03), INCY: 71.57 (+1.99), AMGN: 160.67 (+3.15), LLY: 70.16 (+0.42), BMY: 59.15 (-0.01), RIGL: 2.22 (+0.02), NVO: 43.80 (+1.08), MRK: 57.46 (+0.25), AZN: 70.44 (+0.26), ABBV: 66.21 (+1.86), NVS: 93.91 (+0.66), CELGZ: 3.34 (-0.01)
UCB's Brivaracetam Positive in Phase III Epilepsy Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 4:40PM CDT
UCB SA (UCBJF) announced positive top-line results from a phase III study on epilepsy candidate, brivaracetam.
BIIB: 340.89 (+5.13), VRX: 140.33 (-0.22), GSK: 42.85 (+0.11)
UCB, Dermira Sign Cimzia Dermatology Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 07, 5:10PM CDT
UCB SA (UCBJF) and Dermira have entered into a licensing agreement for the development and commercialization of Cimzia in dermatology.
BIIB: 340.89 (+5.13), ANIP: 55.24 (+1.79), ARIA: 6.81 (+0.15)
UCB's Vimpat Positive for Partial-Onset Seizures - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 30, 10:50AM CDT
UCB SA (UCBJF) announced positive data from two studies on Vimpat as an early adjunctive therapy in adults suffering from partial-onset seizures.
BIIB: 340.89 (+5.13), ANIP: 55.24 (+1.79), ARIA: 6.81 (+0.15)